Interleukin 28A (IL28A) Antibody

Este producto es parte de IFNL3 - interferon lambda 3
Product Graph
286€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Interleukin 28A (IL28A) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx131936
tested applications
WB, IHC, IF/ICC

Description

Interleukin 28A Antibody is a Mouse Monoclonal against Interleukin 28A.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Interleukin 28A (IL28A)
Host
Mouse
Reactivity
Human
Recommended Dilution
WB: 0.01-5 µg/ml, IHC: 5-30 µg/ml, IF/ICC: 5-30 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
Unconjugated
Isotype
IgG2b Kappa
Purification
Purified by Protein A and Protein G affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q8IZJ0
Alias
IL28B,IL28C,IL-28B,IL-28C,IFN-lambda-3,IFN-lambda-4,Cytokine Zcyto22,Interleukin-28B,Interleukin-28C
Background
Antibody anti-IFNL3
Status
RUO

Descripción

Interferon Lambda 3 (IFNL3), also known as IL-28B, is a cytokine that belongs to the Type III interferon family, which plays a critical role in the innate immune system, particularly in antiviral defense. IFNL3, like other Type III interferons, activates signaling pathways that result in the expression of interferon-stimulated genes (ISGs), creating an antiviral state within cells. IFNL3 primarily targets epithelial cells, such as those lining the respiratory tract, gastrointestinal tract, and liver, which are common entry points for viral infections. The discovery of IFNL3 and its genetic variations has been of significant interest, especially due to its role in the treatment and clearance of hepatitis C virus (HCV) infections. Genetic polymorphisms in the IFNL3 gene are strong predictors of treatment response in HCV patients, influencing outcomes of both spontaneous viral clearance and antiviral therapy. This connection has made IFNL3 a focus of research in viral infections, where immune response to chronic infections is crucial.

Related Products

EB0195

Bovine IFNL3 (Interferon lambda 3) ELISA Kit

Ver Producto
EH2057

Human IL28B (Interleukin-28B) ELISA Kit

Ver Producto
Pr23016

Recombinant Human IL-28B

Ver Producto